ATAI Quote, Financials, Valuation and Earnings

Enveric Biosciences, Inc. has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of --. Atai Beckley, Inc.'s return on equity of -91.85% beat Enveric Biosciences, Inc.'s return on equity of -322.21%.

Atai Beckley, Inc. has a consensus price target of $12.27, signalling upside risk potential of 225.54%. On the other hand Enveric Biosciences, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 4963.29%. Given that Enveric Biosciences, Inc. has higher upside potential than Atai Beckley, Inc., analysts believe Enveric Biosciences, Inc. is more attractive than Atai Beckley, Inc..

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Enveric Biosciences, Inc. has a beta of 0.298, suggesting its less volatile than the S&P 500 by 70.169%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enveric Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Enveric Biosciences, Inc. pays out -- of its earnings as a dividend.

Atai Beckley, Inc. quarterly revenues are $749K, which are larger than Enveric Biosciences, Inc. quarterly revenues of --. Atai Beckley, Inc.'s net income of -$61.1M is lower than Enveric Biosciences, Inc.'s net income of -$1.9M. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Enveric Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 231.10x versus 0.02x for Enveric Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of 20.83%. Atai Beckley, Inc.'s return on equity of -91.85% beat Johnson & Johnson's return on equity of 33.27%.

Atai Beckley, Inc. has a consensus price target of $12.27, signalling upside risk potential of 225.54%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Atai Beckley, Inc. has higher upside potential than Johnson & Johnson, analysts believe Atai Beckley, Inc. is more attractive than Johnson & Johnson.

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Atai Beckley, Inc. quarterly revenues are $749K, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Atai Beckley, Inc.'s net income of -$61.1M is lower than Johnson & Johnson's net income of $5.1B. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 231.10x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics, Inc. has a net margin of -8157.28% compared to Atai Beckley, Inc.'s net margin of --. Atai Beckley, Inc.'s return on equity of -91.85% beat Trevi Therapeutics, Inc.'s return on equity of -35.48%.

Atai Beckley, Inc. has a consensus price target of $12.27, signalling upside risk potential of 225.54%. On the other hand Trevi Therapeutics, Inc. has an analysts' consensus of $21.55 which suggests that it could grow by 88.01%. Given that Atai Beckley, Inc. has higher upside potential than Trevi Therapeutics, Inc., analysts believe Atai Beckley, Inc. is more attractive than Trevi Therapeutics, Inc..

Atai Beckley, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Trevi Therapeutics, Inc. has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.125%.

Atai Beckley, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atai Beckley, Inc. pays -- of its earnings as a dividend. Trevi Therapeutics, Inc. pays out -- of its earnings as a dividend.

Atai Beckley, Inc. quarterly revenues are $749K, which are larger than Trevi Therapeutics, Inc. quarterly revenues of --. Atai Beckley, Inc.'s net income of -$61.1M is lower than Trevi Therapeutics, Inc.'s net income of -$11.8M. Notably, Atai Beckley, Inc.'s price-to-earnings ratio is -- while Trevi Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atai Beckley, Inc. is 231.10x versus -- for Trevi Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.